These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8369784)

  • 21. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.
    Zent C; Smith P
    Tuber Lung Dis; 1995 Apr; 76(2):109-13. PubMed ID: 7780091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
    Kumar AKH; Kadam A; Karunaianantham R; Tamizhselvan M; Padmapriyadarsini C; Mohan A; Jeyadeepa B; Radhakrishnan A; Singh UB; Bapat S; Mane A; Kumar P; Mamulwar M; Bhavani PK; Haribabu H; Rath N; Guleria R; Khan AM; Menon J;
    Ther Drug Monit; 2024 Jun; 46(3):370-375. PubMed ID: 38019456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
    Semenova OV
    Probl Tuberk Bolezn Legk; 2003; (11):22-5. PubMed ID: 14689793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
    Agounitestane D; Chiheb M; Khaled S; Ait Khaled N; Boulahbal F; Chaulet P
    Rev Mal Respir; 1990; 7(3):209-13. PubMed ID: 2114029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
    Hao LH; Guo SC; Liu CC; Zhu H; Wang B; Fu L; Chen MT; Zhou L; Chi JY; Yang W; Nie WJ; Lu Y
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1505-12. PubMed ID: 25517820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
    Façanha MC; Gondim AM; Pinheiro VG; Barroso EC; Peloquin CA; Guerrant RL; Lima AA
    Braz J Infect Dis; 2009 Jun; 13(3):210-7. PubMed ID: 20191199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
    Bellabas M; Khaled S; Khaled NA; Boulahbal F; Chaulet P
    Rev Mal Respir; 1989; 6(1):59-64. PubMed ID: 2648511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.